Dr. Fairooz Kabbinavar M.D. serves as Senior Vice President, Clinical Development of the Company. Dr. Kabbinavar served as a principal medical director at Genentech Inc., a biotechnology company, from November 2016 to April 2019, where he led the development of the cancer immunotherapy TECENTRIQ® (atezolizumab) in the small cell lung cancer registration study and supplemental biologics license application, as well as serving as the clinical lead for the head and neck cancer program. Prior to that, Dr. Kabbinavar held academic appointments at the University of California, Los Angeles (“UCLA”) from July 1994 to October 2016, including professor of medicine and urologic oncology, Henry Alvin and Carrie L. Meinhardt endowed chair in kidney cancer research, director of the medical oncology program in genitourinary and lung cancers and co-director of the brain tumor program. Dr. Kabbinavar is board-certified by the American Board of Internal Medicine in Medical Oncology. Dr. Kabbinavar holds B.Sc., MBBS and M.D. degrees from Nagpur University. He completed his postdoctoral research fellowship at UCLA’s Division of Hematology/Oncology, as well as a clinical hematology/oncology fellowship, internship and residency at Beth Israel Deaconess Medical Center.
As the Senior Vice President и Clinical Development of Tocagen, the total compensation of Fairooz Kabbinavar at Tocagen is $1,139,660. There are no executives at Tocagen getting paid more.
Fairooz Kabbinavar is 63, he's been the Senior Vice President и Clinical Development of Tocagen since 2019. There are 1 older and 4 younger executives at Tocagen. The oldest executive at Tocagen, Inc. is Thomas Darcy, 70, who is the Director.
Fairooz's mailing address filed with the SEC is C/O CARDIFF ONCOLOGY, INC., 11055 FLINTKOTE AVE, SAN DIEGO, CA, 92121.
Over the last 7 years, insiders at Tocagen have traded over $0 worth of Tocagen stock and bought 339,950 units worth $1,867,749 . The most active insiders traders include Faheem Hasnain, Steven Michael Oliveira и Franklin M Berger. On average, Tocagen executives and independent directors trade stock every 99 days with the average trade being worth of $2,157,169. The most recent stock trade was executed by Steven Michael Oliveira on 14 April 2020, trading 74,301 units of TOCA stock currently worth $88,418.
Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA.
Tocagen executives and other stock owners filed with the SEC include: